Silicon as a Bioisostere for Carbon in Drug Design

In the pursuit of novel therapeutic agents, medicinal chemists often employ the concept of bioisosterism – the replacement of one atom or group in a molecule with another atom or group having similar physical or chemical properties. Silicon, due to its chemical similarity to carbon, has emerged as a fascinating bioisostere in drug design.

Silicon in Medicinal Chemistry

Silicon, located directly below carbon in the periodic table, shares many of its chemical properties but also offers distinct advantages as a bioisostere:

  1. Larger Atomic Radius: Silicon has a larger atomic radius than carbon, which can influence molecular shape and steric interactions.
  2. Increased Lipophilicity: Compounds with silicon may exhibit increased lipophilicity compared to their carbon analogs, potentially enhancing cell membrane permeability. See this case study for an illustration of this effect.
  3. Metabolic Stability: Silicon-containing compounds often show enhanced metabolic stability, which can be beneficial in extending the drug's effective half-life in the body.

Looking at a 3D model makes these differences obvious: the Si–C bonds in silafluofen are substantially longer than C–C bonds, which alters the shape of the molecule and the dihedral preferences of other bonds.

Applications of Silicon Bioisosteres

Silicon in Drug Candidates

Silicon has been used to replace carbon in various functional groups like alcohols, ketones, and amides. These modifications have resulted in compounds with altered pharmacokinetic and pharmacodynamic profiles, sometimes leading to improved therapeutic properties.

Case Studies

Several studies have demonstrated the potential of silicon bioisosteres. For instance, replacing a carbon atom with silicon in certain compounds has resulted in increased potency, selectivity, and metabolic stability. Here's some case studies:

There are lots more papers out there: see for instance this recent review.

Challenges in Silicon Bioisosterism

Despite its potential, the use of silicon as a bioisostere presents challenges:

  1. Synthetic Difficulty: Introducing silicon into organic molecules can be more challenging than traditional carbon-based synthesis. Nevertheless, more and more Si-containing building blocks are now available: see, for instance, this list from Enamine.
  2. Predicting Biological Effects: The effects of silicon substitution on biological systems are not always predictable, necessitating extensive testing.

Computational Chemistry and Silicon Bioisosteres

Advanced computational tools are crucial in predicting the effects of silicon substitution in drug molecules. Quantum chemistry, accessible through platforms like Rowan, can provide insights into the electronic structure, reactivity, and conformational changes resulting from silicon substitution. This predictive power is invaluable in the early stages of drug design. Computational studies also aid in understanding how silicon substitution impacts a drug's metabolism, helping to predict its pharmacokinetic behavior.

Conclusion

The use of silicon as a bioisostere for carbon in drug design is an area of growing interest. While challenges remain, the potential for developing novel therapeutics with improved properties is significant. Continued research, aided by computational chemistry tools like those offered by Rowan, is essential for advancing our understanding and application of silicon bioisosteres in medicinal chemistry.

For researchers interested in exploring the innovative realm of silicon bioisosteres, Rowan provides the computational platform necessary for such advanced studies. Begin your journey in pioneering drug design by creating an account at labs.rowansci.com/create-account.

Banner background image

What to Read Next

Solvent-Dependent Conformer Search

Solvent-Dependent Conformer Search

a good conformer is hard to find; clustering and the ReSCoSS workflow; Rowan's implementation, with some expert help; a demonstration on maraviroc
Feb 26, 2026 · Corin Wagen and Ari Wagen
How to Predict Protein–Ligand Binding Affinity

How to Predict Protein–Ligand Binding Affinity

A comparison of seven different approaches to predicting binding affinity.
Feb 13, 2026 · Corin Wagen
SAPT, Protein Preparation, and Starling-Based Microscopic pKa

SAPT, Protein Preparation, and Starling-Based Microscopic pKa

interaction energy decomposition w/ SAPT0 & a warning; making protein preparation more granular; catching forcefield errors earlier; microscopic pKa via Starling; internship applications now open
Feb 12, 2026 · Corin Wagen, Jonathon Vandezande, Ari Wagen, and Eli Mann
Credits FAQ

Credits FAQ

How credits work, why Rowan tracks usage with credits, and how these numbers translate into real-world workflows.
Feb 9, 2026 · Corin Wagen and Ari Wagen
Analogue Docking, Protein MD, Multiple Co-Folding Samples, Speed Estimates, and 2FA

Analogue Docking, Protein MD, Multiple Co-Folding Samples, Speed Estimates, and 2FA

docking analogues to a template; running MD on proteins w/o ligands; generating multiple structures with Boltz & Chai; runtime estimates & dispatch information; two-factor authentication; speedups
Jan 28, 2026 · Corin Wagen, Ari Wagen, and Spencer Schneider
Predicting Permeability for Small Molecules

Predicting Permeability for Small Molecules

why permeability matters; different experimental and computational approaches; Rowan’s supported methods; an example script
Jan 9, 2026 · Corin Wagen, Eli Mann, and Ari Wagen
2025 in Review

2025 in Review

looking back on the last year for Rowan
Jan 1, 2026 · Corin Wagen
Making Rowan Even Easier To Use

Making Rowan Even Easier To Use

easier sign-on; layered security with IP whitelists; clearer costs; solvent-aware conformer searching; interviews with onepot and bioArena
Dec 16, 2025 · Ari Wagen, Spencer Schneider, and Corin Wagen
Batch Calculations Through Rowan's API

Batch Calculations Through Rowan's API

How to efficiently submit and analyze lots of workflows through Rowan's free Python API.
Dec 10, 2025 · Corin Wagen
Building BioArena: Kat Yenko on Evaluating Scientific AI Agents

Building BioArena: Kat Yenko on Evaluating Scientific AI Agents

Ari interviews Kat Yenko about her vision for BioArena, what led her to get started, and how to evaluate the utility of frontier models for real-world science.
Dec 9, 2025 · Ari Wagen